Combined Placental Mesenchymal Stem Cells with Guided Nanoparticles Effective Against Diabetic Nephropathy in Mouse Model

References

• Ali MK, Pearson-Stuttard J, Selvin E, et al. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia. 2022;65(1):3–13. doi:10.1007/s00125-021-05585-2
   PubMed Web of Science ®Google Scholar
• Crandall JP, Knowler WC, Kahn SE, et al. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(7):382–393. doi:10.1038/ncpendmet0843
   PubMedGoogle Scholar
• Golden SH. Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications. Am J Cardiol. 2011;108(3 Suppl):59b–67b. doi:10.1016/j.amjcard.2011.03.017
   PubMed Web of Science ®Google Scholar
• Molitch ME. Nephropathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S79–83.
   PubMedGoogle Scholar
• Espinel E, Agraz I, Ibernon M, et al. Renal biopsy in type 2 diabetic patients. J Clin Med. 2015;4(5):998–1009. doi:10.3390/jcm4050998
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019;19(12):151. doi:10.1007/s11892-019-1270-y
   PubMed Web of Science ®Google Scholar
• Tögel F, Westenfelder C. Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn. 2007;236(12):3321–3331. doi:10.1002/dvdy.21258
   PubMed Web of Science ®Google Scholar
• Xiang E, Han B, Zhang Q, et al. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020;11(1):336. doi:10.1186/s13287-020-01852-y
   PubMed Web of Science ®Google Scholar
• Lee SE, Chathuranga K, Lee J-S, et al. Mesenchymal stem cells prevent the progression of diabetic nephropathy by improving mitochondrial function in tubular epithelial cells. Exp Mol Med. 2019;51(7):1–14. doi:10.1038/s12276-019-0299-y
   Google Scholar
• Ezquer F, Ezquer M, Simon V, et al. Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant. 2009;15(11):1354–1365. doi:10.1016/j.bbmt.2009.07.022
   PubMed Web of Science ®Google Scholar
• Wang S, Li Y, Zhao J, et al. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant. 2013;19(4):538–546. doi:10.1016/j.bbmt.2013.01.001
   PubMed Web of Science ®Google Scholar
• Zhang L, Li K, Liu X, et al. Repeated systemic administration of human adipose-derived stem cells attenuates overt diabetic nephropathy in rats. Stem Cells Dev. 2013;22(23):3074–3086. doi:10.1089/scd.2013.0142
   PubMed Web of Science ®Google Scholar
• Li X, Bai J, Ji X, et al. Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med. 2014;34(3):695–704. doi:10.3892/ijmm.2014.1821
   PubMed Web of Science ®Google Scholar
• Li X, Wei Z, Wu L, et al. Efficacy of Fe 3 O 4 @polydopamine nanoparticle-labeled human umbilical cord Wharton’s jelly-derived mesenchymal stem cells in the treatment of streptozotocin-induced diabetes in rats. Biomater Sci. 2020;8(19):5362–5375. doi:10.1039/D0BM01076F
   PubMed Web of Science ®Google Scholar
• Hour FQ, Moghadam AJ, Shakeri-Zadeh A, et al. Magnetic targeted delivery of the SPIONs-labeled mesenchymal stem cells derived from human wharton’s jelly in alzheimer’s rat models. J Control Release. 2020;321:430–441. doi:10.1016/j.jconrel.2020.02.035
   PubMed Web of Science ®Google Scholar
• Chaudeurge A, Wilhelm C, Chen-Tournoux A, et al. Can magnetic targeting of magnetically labeled circulating cells optimize intramyocardial cell retention? Cell Transplant. 2012;21(4):679–691. doi:10.3727/096368911X612440
   PubMed Web of Science ®Google Scholar
• Saldanha KJ, Doan RP, Ainslie KM, et al. Micrometer-sized iron oxide particle labeling of mesenchymal stem cells for magnetic resonance imaging-based monitoring of cartilage tissue engineering. Magn Reson Imaging. 2011;29(1):40–49. doi:10.1016/j.mri.2010.07.015
   PubMed Web of Science ®Google Scholar
• Hill JM, Dick AJ, Raman VK, et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation. 2003;108(8):1009–1014. doi:10.1161/01.CIR.0000084537.66419.7A
   PubMed Web of Science ®Google Scholar
• Ma R, He Y, Fang Q, et al. Ferulic acid ameliorates renal injury via improving autophagy to inhibit inflammation in diabetic nephropathy mice. Biomed Pharmacother. 2022;153:113424. doi:10.1016/j.biopha.2022.113424
   PubMed Web of Science ®Google Scholar
• Garzón I, Pérez-Köhler B, Garrido-Gómez J, et al. Evaluation of the cell viability of human Wharton’s jelly stem cells for use in cell therapy. Tissue Eng Part C Methods. 2012;18(6):408–419. doi:10.1089/ten.tec.2011.0508
   PubMed Web of Science ®Google Scholar
• Rodriguez-Morata A, Garzon I, Alaminos M, et al. Cell viability and prostacyclin release in cultured human umbilical vein endothelial cells. Ann Vasc Surg. 2008;22(3):440–448. doi:10.1016/j.avsg.2008.03.004
   PubMed Web of Science ®Google Scholar
• González-Andrades M, Garzón I, Gascón MI, et al. Sequential development of intercellular junctions in bioengineered human corneas. J Tissue Eng Regen Med. 2009;3(6):442–449. doi:10.1002/term.178
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lewis B, Steiner MS, et al. Superparamagnetic iron oxide nanoparticles for direct labeling of stem cells and in vivo MRI tracking. Contrast Media Mol Imaging. 2016;11(1):55–64. doi:10.1002/cmmi.1658
   PubMed Web of Science ®Google Scholar
• Soenen SJ, De Cuyper M. Assessing cytotoxicity of (iron oxide-based) nanoparticles: an overview of different methods exemplified with cationic magnetoliposomes. Contrast Media Mol Imaging. 2009;4(5):207–219. doi:10.1002/cmmi.282
   PubMed Web of Science ®Google Scholar
• Dominici M. Minimal criteria for defining multipotent mesenchymal stromal cells. Int Soc Cell Therapy Position State Cytoth. 2006;8(4):315–317.
   Google Scholar
• Nombela-Arrieta C, Ritz J, Silberstein LE. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol. 2011;12(2):126–131. doi:10.1038/nrm3049
   PubMed Web of Science ®Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726–736. doi:10.1038/nri2395
   PubMed Web of Science ®Google Scholar
• Ezquer FE, Ezquer ME, Parrau DB, et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008;14(6):631–640. doi:10.1016/j.bbmt.2008.01.006
   PubMed Web of Science ®Google Scholar
• Li H, Rong P, Ma X, et al. Mouse umbilical cord mesenchymal stem cell paracrine alleviates renal fibrosis in diabetic nephropathy by reducing myofibroblast transdifferentiation and cell proliferation and upregulating mmps in mesangial cells. J Diabetes Res. 2020;2020:3847171. doi:10.1155/2020/3847171
   PubMed Web of Science ®Google Scholar
• Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007;13(11):1349–1358. doi:10.1038/nm1667
   PubMed Web of Science ®Google Scholar
• Jha JC, Thallas-Bonke V, Banal C, et al. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Diabetologia. 2016;59(2):379–389. doi:10.1007/s00125-015-3796-0
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M, Masiero A, Roiter AM, et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes. 2003;52(4):1031–1035. doi:10.2337/diabetes.52.4.1031
   PubMed Web of Science ®Google Scholar
• Semedo P, Correa-Costa M, Antonio Cenedeze M, et al. Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells. 2009;27(12):3063–3073. doi:10.1002/stem.214
   PubMed Web of Science ®Google Scholar
• Mouiseddine M. Intravenous human mesenchymal stem cells transplantation in NOD/SCID mice preserve liver integrity of irradiation damage. Methods Mol Biol. 2012;826:179–188.
   PubMedGoogle Scholar
• Schrepfer S, Deuse T, Reichenspurner H, et al. Stem cell transplantation: the lung barrier. Transplant Proc. 2007;39(2):573–576. doi:10.1016/j.transproceed.2006.12.019
   PubMed Web of Science ®Google Scholar
• Zonta S, De Martino M, Bedino G, et al. Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial? Transplant Proc. 2010;42(4):1336–1340. doi:10.1016/j.transproceed.2010.03.081
   PubMed Web of Science ®Google Scholar
• Donate-Correa J, Luis-Rodríguez D, Martín-Núñez E, et al. Inflammatory targets in diabetic nephropathy. J Clin Med. 2020;9(2):458. doi:10.3390/jcm9020458
   PubMed Web of Science ®Google Scholar
• Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant. 2005;20(12):2601–2604. doi:10.1093/ndt/gfi155
   PubMed Web of Science ®Google Scholar
• Wong CK, Ho AWY, Tong PCY, et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol. 2007;149(1):123–131. doi:10.1111/j.1365-2249.2007.03389.x
   PubMed Web of Science ®Google Scholar
• Walther CP, Navaneethan SD. Inflammation as a therapeutic target to improve vascular function in kidney disease. J Am Soc Nephrol. 2017;28(3):723–725. doi:10.1681/ASN.2016111173
   PubMed Web of Science ®Google Scholar
• Calle P, Hotter G. Macrophage phenotype and fibrosis in diabetic nephropathy. Int J Mol Sci. 2020;21(8):2806. doi:10.3390/ijms21082806
   PubMed Web of Science ®Google Scholar
• Nguyen D, Ping FU, Mu W, et al. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology. 2006;11(3):226–231. doi:10.1111/j.1440-1797.2006.00576.x
   PubMed Web of Science ®Google Scholar
• Awad AS, Kinsey GR, Khutsishvili K, et al. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol. 2011;301(6):F1358–66. doi:10.1152/ajprenal.00332.2011
   PubMed Web of Science ®Google Scholar
• Huang M, Zhu Z, Nong C, et al. Bioinformatics analysis identifies diagnostic biomarkers and their correlation with immune infiltration in diabetic nephropathy. Ann Transl Med. 2022;10(12):669. doi:10.21037/atm-22-1682
   PubMed Web of Science ®Google Scholar
• Zhang Y, Le X, Zheng S, et al. MicroRNA-146a-5p-modified human umbilical cord mesenchymal stem cells enhance protection against diabetic nephropathy in rats through facilitating M2 macrophage polarization. Stem Cell Res Ther. 2022;13(1):171. doi:10.1186/s13287-022-02855-7
   PubMed Web of Science ®Google Scholar
• Zheng S, Zhang K, Zhang Y, et al. Human umbilical cord mesenchymal stem cells inhibit pyroptosis of renal tubular epithelial cells through mir-342-3p/caspase 1 signaling pathway in diabetic nephropathy. Stem Cells Int. 2023;2023:5584894. doi:10.1155/2023/5584894
   PubMed Web of Science ®Google Scholar
• Shao BY, Zhang S-F, Li H-D, et al. Epigenetics and inflammation in diabetic nephropathy. Front Physiol. 2021;12:649587. doi:10.3389/fphys.2021.649587
   PubMed Web of Science ®Google Scholar
• Ina K, Kitamura H, Tatsukawa S, et al. Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy. Med Electron Microsc. 2002;35(2):87–95. doi:10.1007/s007950200011
   PubMedGoogle Scholar
• An X, Liao G, Chen Y, et al. Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model. Stem Cell Res Ther. 2019;10(1):363. doi:10.1186/s13287-019-1401-z
   PubMed Web of Science ®Google Scholar